Avirmax develops rAAV-mediated ophthalmic therapeutics.
Avirmax Inc. is an integrated gene therapy platform company dedicated to:
· AAV capsid engineering with multiple proprietary capsids ready for human trial;
· Multiple innovative AAV products under development for wAMD, PCV, DME, RVO,
dAMD, and glaucoma at various development stages up to IND filing;
· AAV production technologies for in-house and customer projects.